{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:28:10Z","timestamp":1793978890527,"version":"4.8.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013101","name":"Scientific Research Plan Projects of Shaanxi Education Department","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007128","name":"Natural Science Foundation of Shaanxi Province","doi-asserted-by":"publisher","award":["2022JQ-140"],"award-info":[{"award-number":["2022JQ-140"]}],"id":[{"id":"10.13039\/501100007128","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejmech.2026.119231","type":"journal-article","created":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T14:11:08Z","timestamp":1786889468000},"page":"119231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design and synthesis of the first PARP1 and PRMT5 dual inhibitors for the treatment of breast cancer"],"prefix":"10.1016","volume":"319","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2644-1121","authenticated-orcid":false,"given":"Ying","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuguang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangchao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejmech.2026.119231_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119231_bib2","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119231_bib3","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.cell.2023.01.040","article-title":"Deciphering breast cancer: from biology to the clinic","volume":"186","author":"Nolan","year":"2023","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119231_bib4","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.ejmech.2026.119231_bib5","article-title":"Current molecular combination therapies used for the treatment of breast cancer","volume":"23","author":"Wang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119231_bib6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119231_bib7","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119231_bib8","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119231_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2019.102651","article-title":"PARP-1 and its associated nucleases in DNA damage response","volume":"81","author":"Wang","year":"2019","journal-title":"DNA Repair"},{"issue":"14","key":"10.1016\/j.ejmech.2026.119231_bib10","doi-asserted-by":"crossref","DOI":"10.1172\/JCI181062","article-title":"BRCAness, DNA gaps, and gain and loss of PARP inhibitor\u2013induced synthetic lethality","volume":"134","author":"Li","year":"2024","journal-title":"J. Clin. Investig."},{"issue":"6330","key":"10.1016\/j.ejmech.2026.119231_bib11","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.ejmech.2026.119231_bib12","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","article-title":"Poly (ADP-ribose) polymerase inhibition: past, present and future","volume":"19","author":"Curtin","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"27","key":"10.1016\/j.ejmech.2026.119231_bib13","doi-asserted-by":"crossref","first-page":"10502","DOI":"10.1074\/jbc.TM118.000371","article-title":"How cells ensure correct repair of DNA double-strand breaks","volume":"293","author":"Her","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119231_bib14","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2147\/CLEP.S206949","article-title":"A systematic review of the international prevalence of BRCA mutation in breast cancer","volume":"11","author":"Armstrong","year":"2019","journal-title":"Clin. Epidemiol."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119231_bib15","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa2005936","article-title":"A population-based study of genes previously implicated in breast cancer","volume":"384","author":"Hu","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119231_bib16","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1001\/jamaoncol.2023.7322","article-title":"PARP inhibitors for breast cancer treatment: a review","volume":"10","author":"Morganti","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejmech.2026.119231_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1441222","article-title":"Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer","volume":"14","author":"Xie","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2026.119231_bib18","article-title":"Targeting replication fork processing synergizes with PARP inhibition to potentiate lethality in homologous recombination proficient ovarian cancers","volume":"12","author":"Bellare","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ejmech.2026.119231_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2023.106443","article-title":"Functional inhibition of RECQL5 helicase elicits non-homologous end joining response and sensitivity of breast cancers to PARP inhibitor","volume":"161","author":"Philip","year":"2023","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"19","key":"10.1016\/j.ejmech.2026.119231_bib20","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery: miniperspective","volume":"57","author":"Anighoro","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119231_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117937","article-title":"Poly (ADP-ribose) polymerase-1 (PARP1)-based dual inhibitors targeting cancer synthetic lethality (2022-present): advances and perspectives","volume":"297","author":"Ye","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"17","key":"10.1016\/j.ejmech.2026.119231_bib22","doi-asserted-by":"crossref","first-page":"12630","DOI":"10.1021\/acs.jmedchem.1c00567","article-title":"Discovery of first-in-class dual PARP and EZH2 inhibitors for triple-negative breast cancer with wild-type BRCA","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119231_bib23","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1021\/acs.jmedchem.4c00077","article-title":"Rational design of PARP1\/c-Met dual inhibitors for overcoming PARP1 inhibitor resistance induced by c-Met overexpression","volume":"67","author":"Sun","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119231_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115943","article-title":"Design and synthesis of the first PARP-1 and proteasome dual inhibitors to treat breast cancer","volume":"264","author":"He","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119231_bib25","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1021\/acs.jmedchem.5c02659","article-title":"Dual PARP\/NAMPT inhibitors for BRCA wild-type triple-negative breast cancer: disrupting homologous recombination repair and activating antitumor immunity","volume":"69","author":"Wang","year":"2026","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119231_bib26","doi-asserted-by":"crossref","first-page":"8243","DOI":"10.1074\/jbc.M109984200","article-title":"A novel WD repeat protein component of the methylosome binds Sm proteins","volume":"277","author":"Friesen","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"17","key":"10.1016\/j.ejmech.2026.119231_bib27","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1016\/j.molcel.2021.07.019","article-title":"Molecular basis for substrate recruitment to the PRMT5 methylosome","volume":"81","author":"Mulvaney","year":"2021","journal-title":"Mol. Cell"},{"issue":"13","key":"10.1016\/j.ejmech.2026.119231_bib28","doi-asserted-by":"crossref","first-page":"8407","DOI":"10.1021\/acs.jmedchem.3c00250","article-title":"Targeting arginine methyltransferase PRMT5 for cancer therapy: updated progress and novel strategies","volume":"66","author":"Zheng","year":"2023","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119231_bib29","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1158\/0008-5472.CAN-23-1899","article-title":"CircMMP2 (6, 7) cooperates with \u03b2-catenin and PRMT5 to disrupt bone homeostasis and promote breast cancer bone metastasis","volume":"84","author":"Xu","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119231_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114842","article-title":"Medicinal chemistry strategies targeting PRMT5 for cancer therapy","volume":"244","author":"Fu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119231_bib31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s42764-022-00095-w","article-title":"PRMT1 and PRMT5: on the road of homologous recombination and non-homologous end joining","volume":"4","author":"Yin","year":"2023","journal-title":"Genome Instability Disease"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119231_bib32","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1186\/s12885-023-11260-z","article-title":"Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of niraparib, a PARP inhibitor, in models of breast and ovarian cancer","volume":"23","author":"O'Brien","year":"2023","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.ejmech.2026.119231_bib33","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1158\/2767-9764.CRC-23-0070","article-title":"PRMT5 inhibitors regulate DNA damage repair pathways in cancer cells and improve response to PARP inhibition and chemotherapies","volume":"3","author":"Carter","year":"2023","journal-title":"Cancer Res. Commun."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119231_bib34","article-title":"PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition","volume":"4","author":"Li","year":"2023","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119231_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-20696-1","article-title":"PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1\/2 and MTAP status in breast cancer cells","volume":"15","author":"Suresh","year":"2025","journal-title":"Sci. Rep."},{"issue":"32","key":"10.1016\/j.ejmech.2026.119231_bib36","doi-asserted-by":"crossref","first-page":"19415","DOI":"10.1073\/pnas.2009237117","article-title":"FEN1 endonuclease as a therapeutic target for human cancers with defects in homologous recombination","volume":"117","author":"Guo","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119231_bib37","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.molcel.2015.10.013","article-title":"PARP-1 activation requires local unfolding of an autoinhibitory domain","volume":"60","author":"Dawicki-McKenna","year":"2015","journal-title":"Mol. Cell"},{"issue":"6","key":"10.1016\/j.ejmech.2026.119231_bib38","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/nchembio.1810","article-title":"A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models","volume":"11","author":"Chan-Penebre","year":"2015","journal-title":"Nat. Chem. Biol."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119231_bib39","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1021\/acs.jmedchem.6b00990","article-title":"Structural basis for potency and promiscuity in Poly(ADP-ribose) polymerase (PARP) and tankyrase inhibitors","volume":"60","author":"Thorsell","year":"2017","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119231_bib40","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1021\/acs.jmedchem.3c02096","article-title":"Discovery and proof of concept of potent dual Pol\u03b8\/PARP inhibitors for efficient treatment of homologous recombination-deficient tumors","volume":"67","author":"Ma","year":"2024","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.ejmech.2026.119231_bib41","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1101\/gad.13.20.2633","article-title":"XRCC3 promotes homology-directed repair of DNA damage in mammalian cells","volume":"13","author":"Pierce","year":"1999","journal-title":"Genes Dev."},{"issue":"23","key":"10.1016\/j.ejmech.2026.119231_bib42","doi-asserted-by":"crossref","first-page":"17413","DOI":"10.1021\/acs.jmedchem.1c01535","article-title":"Discovery of potent and novel dual PARP\/BRD4 inhibitors for efficient treatment of pancreatic cancer","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119231_bib43","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1039\/C7MB00391A","article-title":"Development of an AlphaLISA high throughput technique to screen for small molecule inhibitors targeting protein arginine methyltransferases","volume":"13","author":"Prabhu","year":"2017","journal-title":"Mol. Biosyst."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:03:55Z","timestamp":1793977435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426006768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":43,"alternative-id":["S0223523426006768"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119231","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and synthesis of the first PARP1 and PRMT5 dual inhibitors for the treatment of breast cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119231","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119231"}}